• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
27 results

Melanin Decomposition Inhibitor

Docket 16/75,828, U.S. Patent Application (Aug. 6, 2018)
Art Group1628
Case TypeUtility - 514/280000
Class514
Inventor Daiki MURASE
Inventor Akira HACHIYA
Inventor Naoki OYA
...
cite Cite Docket
Analyze

Final Rejection

Document Melanin Decomposition Inhibitor, 16/75,828, No. 1-11-US-160758280VP1 (U.S. Pat. App. Feb. 6, 2020)
All b)C] Some** c)[j None of the: 1.I Certified copies of the priority documents have been received.
As indicated in the Office Action of 06/25/2019, claims 1-11, 13-15, 17-19 and 21 were withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or ...
cite Cite Document
Analyze

Non-Final Rejection

Document Melanin Decomposition Inhibitor, 16/75,828, No. 1-15-US-160758280PP1 (U.S. Pat. App. Jun. 25, 2019)
All b)|:] Some** c)C] None of the: 1..
Claims 1-11, 13-15, 17-19 and 21 were withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim.
cite Cite Document
Analyze

Amendment/Req. Reconsideration-After Non-Final Reject

Document Melanin Decomposition Inhibitor, 16/75,828, No. 1-1-US-160758280RP1 (U.S. Pat. App. Nov. 13, 2019)
In re application of: Inventors: Murase er al.
Confirmation No.: 1355 Applicant: Kao Corporation Art Unit: 1628 Appl.
Nat’l Ph of: PCTJP20l7/004987 Filed: February 10, 2017 Examiner: George W. Kosturko For: Melanin Decomposition Inhibitor Atty.
Amendments to the Claims begin on page 2 of this paper.
Remarks begin on page 10 of this paper.
cite Cite Document
Analyze

Applicant Arguments/Remarks Made in an Amendment

Document Melanin Decomposition Inhibitor, 16/75,828, No. 10-9-US-160758280RP1 (U.S. Pat. App. Nov. 13, 2019)
In the interests of advancing prosecution, independent claim 12 has been amended to recite “darkening the subject’s skin or hair color at [the application] site as a result of the applying.” Browne does not disclose the claim element that recites “darkening that the skin or hair color as a result of the applying” because the patch test for proguanil in Browne was negative.
Preliminarily, Examiner is respectfully asked to note that, as shown on the cover page of the document, the first named inventor of FR 2901133 A1 is “Breton,” not Hue.
As shown below, the property such as darkening skin or hair cannot be considered to be a characteristic feature of the process of administering proguanil that was known or suggested in the art.
The combination of the cited art does not suggest or lead to the conclusion that darkening skin or hair is a natural result or characteristic feature that flows from administering proguanil.
The discussion above shows that the artisan did not have a reasonable expectation of success in reaching an invention in which the skin or hair is darkened by administration of proguanil based on the teachings of Hue, Van Neste and Chulay.
cite Cite Document
Analyze

Authorization for Extension of Time all replies

Document Melanin Decomposition Inhibitor, 16/75,828, No. 1-9-US-160758280TP1 (U.S. Pat. App. Nov. 13, 2019)
In the interests of advancing prosecution, independent claim 12 has been amended to recite “darkening the subject’s skin or hair color at [the application] site as a result of the applying.” Browne does not disclose the claim element that recites “darkening that the skin or hair color as a result of the applying” because the patch test for proguanil in Browne was negative.
Preliminarily, Examiner is respectfully asked to note that, as shown on the cover page of the document, the first named inventor of FR 2901133 A1 is “Breton,” not Hue.
As shown below, the property such as darkening skin or hair cannot be considered to be a characteristic feature of the process of administering proguanil that was known or suggested in the art.
The combination of the cited art does not suggest or lead to the conclusion that darkening skin or hair is a natural result or characteristic feature that flows from administering proguanil.
The discussion above shows that the artisan did not have a reasonable expectation of success in reaching an invention in which the skin or hair is darkened by administration of proguanil based on the teachings of Hue, Van Neste and Chulay.
cite Cite Document
Analyze

Extension of Time

Document Melanin Decomposition Inhibitor, 16/75,828, No. 66-1-US-160758280SP1 (U.S. Pat. App. Nov. 13, 2019)
DEPARTMENT OF COMMERCE Under the Paoerwork Reduction Act of 1995, no oersons are re-uired to res-ond to a collection of information unless it dis-la s a valid OMB control number.
The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number 19'0036 Payment made via EFS-Web.
I am the This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above-identified application.
QRM Signature Michele A. Cimbala Typed or printed name November 13, 2019 Date {202) 371-2600 Telephone Number NOTE: This form must be signed in accordance with 37 CFR 1.33.
The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application.
cite Cite Document
Analyze

Examiner's search strategy and results

Document Melanin Decomposition Inhibitor, 16/75,828, No. 26-33-US-160758280VP1 (U.S. Pat. App. Feb. 6, 2020)
Genetic polymorphisms and drug susceptibility in four isolates of Leishmania tropica obtained from Canadian soldiers returning from Afghanistan Plourde, Marie; Coelho, Adriano; Keynan, Yoav; Larios, Oscar E.; Ndao, Momar; Ruest, Annie; Roy, Gaetan; Rubinstein, Ethan; Ouellette, Marc
Tolerability of doxycycline monohydrate salt vs. chloroquine—proguanil in malaria chemoprophylaxis Pages, Frederic; Boutin, Jean—Paul; Meynard, Jean—Baptiste; Keundjian, Annick; Ryfer, Serge; Giurato, Luciano; Baudon, Dominique Institut de Medecine Tropicale du Service de Sante des Armees (IMTSSA), Le Pharo Marseille, Fr.
C/EBPB—LIP induces cancer—type metabolic reprogramming by regulating the let—7/LIN28B circuit in mice Ackermann, Tobias; Hartleben, Goetz; Mueller, Christine; Mastrobuoni, Guido; Groth, Marco; Sterken, Britt A.; Zaini, Mohamad A.; Youssef, Sameh A.; Zuidhof, Hidde R.; Krauss, Sara R.; Kortman, Gertrud; de Haan, Gerald; de Bruin, Alain; Wang, Zhao—Qi; Platzer, Matthias; Kempa, Stefan; Calkhoven, Cornelis
Nijmegen Breakage Syndrome fibroblasts and iPSCs: cellular models for uncovering disease—associated signaling pathways and establishing a screening platform for anti—oxidants Mlody, Barbara; Wruck, Wasco; Martins, Soraia; Sperling, Karl; Adjaye, James Max—Delbrueck—Centrum fuer Molekulare Medizin (MDC), Berlin, 13092, Germany Scientific Reports (2017), 7(1),
Differentiation—inducing and anti—proliferative activities of isoliquiritigenin and all—trans—retinoic acid on B16F0 melanoma cells: Mechanisms profiling by RNA—seq Chen, Xiaoyu; Yang, Ming; Hao, Wenjin; Han, Jichun; Ma, Jun; Wang, Caixia; Sun, Shiguo; Zheng, Qiusheng College of Science, Northwest A&F University, Shaanxi, 712100, Peop.
cite Cite Document
Analyze
1 2 3 >>